Skip to main content
. Author manuscript; available in PMC: 2022 Aug 9.
Published in final edited form as: Anticancer Res. 2021 Nov;41(11):5333–5342. doi: 10.21873/anticanres.15346

Figure 1.

Figure 1.

Kaplan–Meier survival curves of patients with available individual data: A. Progression-free survival (n=39) and B. Overall survival (n=53) of the total pooled cohort; C. Overall survival (n=53) based on primary tumor; D. Overall survival (n=53) based on immune checkpoint inhibitor therapy; E. Overall survival (n=43) based on the use of steroids concurrent to immune checkpoint inhibitor use.